LLY · News · 20261103N
Market Demand - Anti-Obesity
ELI LILLY & Co · 2026-11-03 · Importance 57 · Surprise 64
Third-party reporting said volume growth was 53%, more than offsetting a 15% decline in realized prices in the third quarter. Mounjaro and Zepbound were identified as Lilly’s primary growth engines, and both outperformed consensus expectations. The report points to strong demand for Lilly’s incretin medicines despite lower realized prices.